A multicenter phase II clinical study conducted by the SWOG Cancer Research Network suggests that combination ipilimumab and nivolumab can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to PD-1 inhibitors.
The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP.
